Biologic Therapy in Chronic Obstructive Pulmonary Disease

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD. This review summarizes clinical trials of the use of these novel agents in the management of COPD.

Original languageEnglish (US)
Pages (from-to)345-355
Number of pages11
JournalImmunology and Allergy Clinics of North America
Volume37
Issue number2
DOIs
StatePublished - May 1 2017

Fingerprint

Biological Therapy
Chronic Obstructive Pulmonary Disease
Inflammation
Environmental Exposure
Biological Factors
Clinical Trials
Therapeutics

Keywords

  • Biologic therapy
  • COPD
  • Exacerbation
  • IL-5
  • TNF-alpha

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Biologic Therapy in Chronic Obstructive Pulmonary Disease. / Tripple, Julia; McCracken, Jennifer; Calhoun, William.

In: Immunology and Allergy Clinics of North America, Vol. 37, No. 2, 01.05.2017, p. 345-355.

Research output: Contribution to journalReview article

@article{9c56945eaf8a4e0ea9c2bf8521d406c5,
title = "Biologic Therapy in Chronic Obstructive Pulmonary Disease",
abstract = "Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD. This review summarizes clinical trials of the use of these novel agents in the management of COPD.",
keywords = "Biologic therapy, COPD, Exacerbation, IL-5, TNF-alpha",
author = "Julia Tripple and Jennifer McCracken and William Calhoun",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.iac.2017.01.009",
language = "English (US)",
volume = "37",
pages = "345--355",
journal = "Immunology and Allergy Clinics of North America",
issn = "0889-8561",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Biologic Therapy in Chronic Obstructive Pulmonary Disease

AU - Tripple, Julia

AU - McCracken, Jennifer

AU - Calhoun, William

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD. This review summarizes clinical trials of the use of these novel agents in the management of COPD.

AB - Chronic obstructive pulmonary disease (COPD) is common worldwide. The predominant cause in most COPD is environmental exposure to toxicants. The inflammatory processes in COPD are multifactorial, complex, and interacting, leading to many potential therapeutic targets. Although most typically associated with neutrophilic/macrophagic inflammation (type 1), it is now known that COPD can also be associated with eosinophilic inflammation (type 2), particularly in exacerbations. Accordingly, there is an active program of investigation of highly selective biologic therapeutic agents in the management of COPD. This review summarizes clinical trials of the use of these novel agents in the management of COPD.

KW - Biologic therapy

KW - COPD

KW - Exacerbation

KW - IL-5

KW - TNF-alpha

UR - http://www.scopus.com/inward/record.url?scp=85016471944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016471944&partnerID=8YFLogxK

U2 - 10.1016/j.iac.2017.01.009

DO - 10.1016/j.iac.2017.01.009

M3 - Review article

VL - 37

SP - 345

EP - 355

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

SN - 0889-8561

IS - 2

ER -